{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:16:14Z","timestamp":1781543774967,"version":"3.54.5"},"reference-count":49,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Secukinumab is a fully human monoclonal antibody that targets interleukin (IL)-17A and is used to treat axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). Treating axSpA and PsA can be challenging in patients with comorbidities. In this multicenter retrospective study, we aimed to evaluate the efficacy and safety of secukinumab treatment in patients with axSpA and PsA who had a history of tuberculosis, multiple sclerosis (MS), or congestive heart failure (CHF). Methods: The study included 44 patients with a diagnosis of axSpA and PsA and a history of tuberculosis, MS, or CHF who received secukinumab treatment at 13 centers in our country. Erythrocyte sedimentation rate, C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score CRP, visual analog scale, and Disease Activity Score-28 CRP markers at months 0, 3, and 12 of secukinumab treatment were analyzed. Alongside this, tuberculosis, MS, and CHF were evaluated at follow-up using clinical assessments and imaging methods such as chest radiographs, brain magnetic resonance, and echocardiography. Results: A statistically significant improvement in inflammatory markers and disease activity scores was observed in patients treated with secukinumab. There was no reactivation in patients with a history of tuberculosis. In most MS patients, the disease was stable, while clinical and radiological improvement was observed in one patient. No worsening of CHF stage was observed in patients with a history of CHF. Conclusions: With regular clinical monitoring, secukinumab may be an effective and safe treatment option for axSpA and PsA patients with a history of tuberculosis, MS, or CHF.<\/jats:p>","DOI":"10.3390\/jcm14155181","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:44:45Z","timestamp":1753184685000},"page":"5181","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating Secukinumab as Treatment for Axial Spondyloarthritis and Psoriatic Arthritis in Patients with Comorbidities: Multicenter Real-Life Experience"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4560-1569","authenticated-orcid":false,"given":"Tu\u011fba","family":"Ocak","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Bursa City Hospital, 16250 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-1986","authenticated-orcid":false,"given":"Burcu","family":"Ya\u011f\u0131z","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Uluda\u011f University, 16059 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0298-4157","authenticated-orcid":false,"given":"Belk\u0131s Nihan","family":"Co\u015fkun","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Uluda\u011f University, 16059 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-0282","authenticated-orcid":false,"given":"Gamze","family":"Akkuzu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital, Health Sciences University, 34480 \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe Nur","family":"Bay\u0131nd\u0131r Akba\u015f","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Pamukkale University, 20160 Denizli, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Kuda\u015f","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Istanbul Physical Therapy Rehabilitation Training and Research Hospital, 34180 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"\u0130nan\u00e7","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, \u0130n\u00f6n\u00fc University, 44280 Malatya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"Yo\u011furt\u00e7u","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, \u0130zmir Katip \u00c7elebi University, 35620 \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Ba\u015f\u0131b\u00fcy\u00fck","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Dokuz Eyl\u00fcl University, 35390 \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezgin","family":"Zontul","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Physical Therapy and Rehabilitation, Faculty of Medicine, In\u00f6n\u00fc University, 44280 Malatya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6052-3896","authenticated-orcid":false,"given":"Fatih","family":"Albayrak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Gaziantep Medical Faculty Hospital, 27310 Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynel Abidin","family":"Akar","sequence":"additional","affiliation":[{"name":"Department of Physical Therapy and Rehabilitation, Division of Rheumatology, Dicle University Hospital, 21280 Diyarbak\u0131r, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saliha","family":"Sunkak","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kayseri City Education and Research Hospital, 38080 Kayseri, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selime","family":"Ermurat","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Bursa Y\u00fcksek Ihtisas Training and Research Hospital, 16140 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Tezcan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, G\u00fclhane Faculty of Medicine, University of Health Sciences, 06018 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"K\u00fc\u00e7\u00fck","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Necmettin Erbakan University, 42090 Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8516-9769","authenticated-orcid":false,"given":"Servet","family":"Yolba\u015f","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, \u0130n\u00f6n\u00fc University, 44280 Malatya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-4180","authenticated-orcid":false,"given":"\u0130smail","family":"Sar\u0131","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Dokuz Eyl\u00fcl University, 35390 \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Yi\u011fit","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Pamukkale University, 20160 Denizli, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-1242","authenticated-orcid":false,"given":"Servet","family":"Akar","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, \u0130zmir Katip \u00c7elebi University, 35620 \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fcnyamin","family":"K\u0131sac\u0131k","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sanko University Medical Faculty Hospital, 16049 Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemal","family":"Bes","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital, Health Sciences University, 34480 \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ediz","family":"Dalk\u0131l\u0131\u00e7","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Uluda\u011f University, 16059 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz","family":"Pehlivan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Uluda\u011f University, 16059 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"i77","DOI":"10.1136\/ard.2010.140582","article-title":"Psoriatic arthritis: Update on pathophysiology, assessment and management","volume":"70","author":"Mease","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti\u2013tumor necrosis factor \u03b1 therapy: Results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/2040622317743486","article-title":"New advances in the understanding and treatment of axial spondyloarthritis: From chance to choice","volume":"9","author":"Dubash","year":"2018","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2023 Update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","unstructured":"Elena, S., Cavagna, L., and Caporali, R. (2020). Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics: A review. Int. J. Mol. Sci., 21."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1007\/s10067-023-06630-8","article-title":"Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection","volume":"42","author":"Liu","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/jamaneurol.2024.3524","article-title":"Risk of inflammatory central nervous system diseases after tumor necrosis factor-inhibitor treatment for autoimmune diseases: A systematic review and meta-analysis","volume":"81","author":"Xie","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1111\/ijd.14902","article-title":"Secukinumab: A potential safe option in psoriasis patients affected by multiple sclerosis?","volume":"59","author":"Megna","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_15","first-page":"102936","article-title":"Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases","volume":"51","author":"Cortese","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Caiazzo, G., Fabbrocini, G., Di Caprio, R., Raimondo, A., Scala, E., Balato, N., and Balato, A. (2018). Psoriasis, cardiovascular events, and biologics: Lights and shadows. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01668"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00296-024-05750-x","article-title":"New onset heart failure in adolescents with inflammatory joint disease treated with TNF-\u03b1 inhibitors: A case-based review","volume":"45","author":"Mavrogeni","year":"2024","journal-title":"Rheumatol. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/09546634.2018.1543843","article-title":"Successful Therapy of Plaque-Type Psoriasis with Secukinumab in Patients with Multiple Comorbidities Treated with Previous Biologic Therapies","volume":"29","author":"Lasagni","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e930041","DOI":"10.12659\/AJCR.930041","article-title":"Nonischemic Dilated Cardiomyopathy in Untreated Long-Term Psoriatic Arthritis: A Newly Recognized Association: A Case Report with Mini Review","volume":"22","author":"Alfraji","year":"2021","journal-title":"Am. J. Case Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Frustaci, A., Galea, N., Dominici, L., Verardo, R., Alfarano, M., Scialla, R., and Richetta, A.G. (2023). Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery Following Secukinumab Administration. J. Clin. Med., 12.","DOI":"10.2139\/ssrn.4325223"},{"key":"ref_24","first-page":"e13943","article-title":"Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis","volume":"33","author":"Odorici","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1111\/ajd.13983","article-title":"A case of psoriasis and multiple sclerosis successfully treated with concomitant fingolimod and secukinumab","volume":"64","author":"Megna","year":"2023","journal-title":"Australas. J. Dermatol."},{"key":"ref_26","first-page":"e15715","article-title":"Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: A mini-review with a representative case report","volume":"36","author":"Venturini","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2217\/imt-2021-0128","article-title":"Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: A case series with literature review","volume":"14","author":"Eksin","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00296-025-05902-7","article-title":"Safety and efficacy of IL-17 inhibitors in patients with comorbid multiple sclerosis\/multiple sclerosis-like syndrome: A systematic review","volume":"45","author":"Chaitidis","year":"2025","journal-title":"Rheumatol. Int."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ocak, T., Ya\u011f\u0131z, B., Ocak, B., Yo\u011furt\u00e7u, \u00d6., Ba\u015f\u0131b\u00fcy\u00fck, F., Tezcan, D., Ermurat, S., \u0130nan\u00e7, E., Yamancan, G., and Albayrak, F. (2024). Secukinumab may be an effective treatment option for axial spondyloarthritis and psoriatic arthritis patients with a history of malignancy: Multicenter real-life experience from Turkey. J. Clin. Med., 13.","DOI":"10.3390\/jcm13206216"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_32","unstructured":"Criteria Committee of the New York Heart Association (1994). Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, Little, Brown & Co.. [9th ed.]."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Developed by the Task Force of the European Society of Cardiology (ESC) with the Special Contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0304-3959(83)90126-4","article-title":"The validation of visual analogue scales as ratio scale measures for chronic and experimental pain","volume":"17","author":"Price","year":"1983","journal-title":"Pain"},{"key":"ref_35","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"Lie","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score","volume":"49","author":"Theunisse","year":"1990","journal-title":"Ann. Rheum. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe Psoriasis\u2014Oral Therapy with a New Retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.immunol.19.1.93","article-title":"Immunology of tuberculosis","volume":"19","author":"Flynn","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ni1449","article-title":"IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge","volume":"8","author":"Khader","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","article-title":"Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis","volume":"157","author":"Elewski","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2353\/ajpath.2008.070690","article-title":"Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis","volume":"172","author":"Tzartos","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: Results from a randomized, proof-of-concept study","volume":"263","author":"Havrdova","year":"2016","journal-title":"J. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00109-014-1176-8","article-title":"IL-17A promotes ventricular remodeling after myocardial infarction","volume":"92","author":"Zhou","year":"2014","journal-title":"J. Mol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1161\/CIRCRESAHA.109.213157","article-title":"Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy","volume":"106","author":"Baldeviano","year":"2010","journal-title":"Circ. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1002\/ehf2.14968","article-title":"IL-17 is associated with disease severity and targetable inflammatory processes in heart failure","volume":"11","author":"Baumhove","year":"2024","journal-title":"ESC Heart Fail."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5181\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:13:49Z","timestamp":1760033629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":49,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14155181"],"URL":"https:\/\/doi.org\/10.3390\/jcm14155181","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}